The co-localization of CD147 and CD276 in LRMs, their impact on cancer stemness, and their association with unfavorable clinical outcomes and chemotherapeutic resistance in HER2+ BC and TNBC provide valuable insights into the potential therapeutic targeting of these proteins. Here, CD276 is linked to cancer.